We are live on ! Find out more
KZIA

Kazia Therapeutics
KZIA

5 hedge funds and large institutions have $233K invested in Kazia Therapeutics in 2017 Q3 according to their latest regulatory filings, with funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0% → 0% (+0%)

16% less capital invested

Capital invested by funds: $278K → $233K (-$45K)

29% less funds holding

Funds holding: 7 → 5 (-2)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
5
Holders Change
-2
Holders Change %
-28.57%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$10.2K
2
UBS Group
UBS Group
Switzerland
+$4.92K
3
Bank of America
Bank of America
North Carolina
+$477

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$119K +$10.2K +64 +9%
Renaissance Technologies
2
Renaissance Technologies
New York
$103K – – –
UBS Group
3
UBS Group
Switzerland
$7K +$4.92K +31 +310%
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$4K – – –
Citadel Advisors
5
Citadel Advisors
Florida
– -$16K -90 Closed
Bank of America
6
Bank of America
North Carolina
– +$477 +3 +300%

KZIA Hedge Fund Activity: Q3 2017 in Review

5 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q3 2017, worth a combined $233K — down 16% from $278K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of KZIA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 3 added.

The largest buyer was Morgan Stanley, adding an estimated $10.2K. The largest seller was Citadel Advisors, exiting entirely with an estimated $16K sold.

  • 5 institutional investors held Kazia Therapeutics (KZIA) as of Q3 2017, down from 7 in Q2 2017.
  • Funds reported $233K of Kazia Therapeutics stock for Q3 2017, down 16% quarter-over-quarter.
  • 0 funds opened new Kazia Therapeutics positions in Q3 2017 and 2 closed out, a net change of -2 holders.
  • The largest Kazia Therapeutics buyer in Q3 2017 was Morgan Stanley, an estimated $10.2K added.
  • The largest Kazia Therapeutics seller in Q3 2017 was Citadel Advisors, an estimated $16K sold.

Based on aggregated 13F filings for Q3 2017.